Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia

Next Previous
Trial Profile

Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inclisiran (Primary) ; Rosuvastatin (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms V-DIFFERENCE
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 30 Aug 2025 According to Novartis media release, data from this trial is being presented at 2025 European Society of Cardiology (ESC) Congress, held in Madrid, Spain, from August 29 to September 1, 2025.
  • 30 Aug 2025 Primary endpoint (Proportion of participants achieving individual LDL-C target (55 mg/dL or 70 mg/dL)) has been met.
  • 30 Aug 2025 Results presented in Novartis Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top